CUE
Cue Biopharma, Inc.
A clinical-stage biopharmaceutical company that engineers injectable biologic drugs designed to "cue," or direct, the body's own T cells to treat allergies, autoimmune disorders, and certain cancers. Its Immuno-STAT platform mimics the natural signals the immune system uses to switch specific T cells on or off, aiming to treat disease without the broad side effects of older therapies. Founded in 2014 as Imagen Biopharma, it was renamed Cue Biopharma in 2016 to reflect that guiding "cue" idea — the name itself is the fun fact: it's built on the biological cues its medicines imitate.
CUSIP: 22978P106HealthcareUS1 holder
Total Value
$7.03M
Total Shares
500.0K
Net Share Change
+500.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
